Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent
Evan Rosenbaum1, Sujana Movva1, Ciara Kelly1
1Evan Rosenbaum, MD, Sujana Movva, MD, and Ciara Kelly, MBBCh, BAO, Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY, Weill-Cornell Medical College, Department of Medicine, New York, NY.
JCO Precision Oncology
|June 8, 2022
Abstract
No abstract available in PubMed .
More Related Videos
07:18Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
7.1K
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.1K
